Cancer genome sequencing and its implications for personalized cancer vaccines

Lijin Li; Peter Goedegebuure; Elaine R. Mardis; Matthew J.C. Ellis; Xiuli Zhang; John M. Herndon; Timothy P. Fleming; Beatriz M. Carreno; Ted H. Hansen; William E. Gillanders

doi:10.3390/cancers3044191

Cancer genome sequencing and its implications for personalized cancer vaccines

Lijin Li, Peter Goedegebuure, Elaine R. Mardis, Matthew J.C. Ellis, Xiuli Zhang, John M. Herndon, Timothy P. Fleming, Beatriz M. Carreno, Ted H. Hansen, William E. Gillanders

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

New DNA sequencing platforms have revolutionized human genome sequencing. The dramatic advances in genome sequencing technologies predict that the $1,000 genome will become a reality within the next few years. Applied to cancer, the availability of cancer genome sequences permits real-time decision-making with the potential to affect diagnosis, prognosis, and treatment, and has opened the door towards personalized medicine. A promising strategy is the identification of mutated tumor antigens, and the design of personalized cancer vaccines. Supporting this notion are preliminary analyses of the epitope landscape in breast cancer suggesting that individual tumors express significant numbers of novel antigens to the immune system that can be specifically targeted through cancer vaccines.

Original language	English
Pages (from-to)	4191-4211
Number of pages	21
Journal	Cancers
Volume	3
Issue number	4
DOIs	https://doi.org/10.3390/cancers3044191
State	Published - Dec 2011

Keywords

Cancer genome sequencing
DNA vaccine
Unique tumor antigen

Access to Document

10.3390/cancers3044191

Cite this

@article{625312ba9a154ac3aff705626fdbdaf6,

title = "Cancer genome sequencing and its implications for personalized cancer vaccines",

abstract = "New DNA sequencing platforms have revolutionized human genome sequencing. The dramatic advances in genome sequencing technologies predict that the $1,000 genome will become a reality within the next few years. Applied to cancer, the availability of cancer genome sequences permits real-time decision-making with the potential to affect diagnosis, prognosis, and treatment, and has opened the door towards personalized medicine. A promising strategy is the identification of mutated tumor antigens, and the design of personalized cancer vaccines. Supporting this notion are preliminary analyses of the epitope landscape in breast cancer suggesting that individual tumors express significant numbers of novel antigens to the immune system that can be specifically targeted through cancer vaccines.",

keywords = "Cancer genome sequencing, DNA vaccine, Unique tumor antigen",

author = "Lijin Li and Peter Goedegebuure and Mardis, {Elaine R.} and Ellis, {Matthew J.C.} and Xiuli Zhang and Herndon, {John M.} and Fleming, {Timothy P.} and Carreno, {Beatriz M.} and Hansen, {Ted H.} and Gillanders, {William E.}",

year = "2011",

month = dec,

doi = "10.3390/cancers3044191",

language = "English",

volume = "3",

pages = "4191--4211",

journal = "Cancers",

issn = "2072-6694",

number = "4",

}

TY - JOUR

T1 - Cancer genome sequencing and its implications for personalized cancer vaccines

AU - Li, Lijin

AU - Goedegebuure, Peter

AU - Mardis, Elaine R.

AU - Ellis, Matthew J.C.

AU - Zhang, Xiuli

AU - Herndon, John M.

AU - Fleming, Timothy P.

AU - Carreno, Beatriz M.

AU - Hansen, Ted H.

AU - Gillanders, William E.

PY - 2011/12

Y1 - 2011/12

N2 - New DNA sequencing platforms have revolutionized human genome sequencing. The dramatic advances in genome sequencing technologies predict that the $1,000 genome will become a reality within the next few years. Applied to cancer, the availability of cancer genome sequences permits real-time decision-making with the potential to affect diagnosis, prognosis, and treatment, and has opened the door towards personalized medicine. A promising strategy is the identification of mutated tumor antigens, and the design of personalized cancer vaccines. Supporting this notion are preliminary analyses of the epitope landscape in breast cancer suggesting that individual tumors express significant numbers of novel antigens to the immune system that can be specifically targeted through cancer vaccines.

AB - New DNA sequencing platforms have revolutionized human genome sequencing. The dramatic advances in genome sequencing technologies predict that the $1,000 genome will become a reality within the next few years. Applied to cancer, the availability of cancer genome sequences permits real-time decision-making with the potential to affect diagnosis, prognosis, and treatment, and has opened the door towards personalized medicine. A promising strategy is the identification of mutated tumor antigens, and the design of personalized cancer vaccines. Supporting this notion are preliminary analyses of the epitope landscape in breast cancer suggesting that individual tumors express significant numbers of novel antigens to the immune system that can be specifically targeted through cancer vaccines.

KW - Cancer genome sequencing

KW - DNA vaccine

KW - Unique tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=84055184471&partnerID=8YFLogxK

U2 - 10.3390/cancers3044191

DO - 10.3390/cancers3044191

M3 - Review article

C2 - 24213133

AN - SCOPUS:84055184471

SN - 2072-6694

VL - 3

SP - 4191

EP - 4211

JO - Cancers

JF - Cancers

IS - 4

ER -

Cancer genome sequencing and its implications for personalized cancer vaccines

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this